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An immediate early gene, RTA (reactivation and transcription 
activator) is very important for the viral lytic replication induction 
and shows multifunctions. We still have not understood how the 
factor functions. Guito and Lukac (2012) and Tsai et al. (2012) 
review or report mechanistic regulation of this strong transactiva-
tor, respectively.
Jackson et al. (2012) describe ORF57, which is also an interesting 
and multifunctional protein. This is involved in post-translational 
processes of the viral gene expression as sumoylation and ubiquit-
ination described by Campbell and Izumiya (2012) and Ashizawa 
et al. (2012) respectively. We had believed that K-bZIP, a homolog of 
Epstein-Barr virus Zta was a transactivator and origin recognition 
factor in the lytic replication. K-bZIP, however, has other important 
roles for KSHV lytic replication. In latency, metabolism of LANA 
(latency-associated nuclear antigen) could be critical for KSHV-
induced tumor formation and/or its phenotype.
Viral particle assembly is virologically an exciting and interest-
ing field. There have been few reports on this, Sathish et al. (2012) 
try to search this issue.
The detail replication mechanism of KSHV in both lytic and 
latent phase has been still unclear. In latency, the virus is supposed 
to utilize host replication machinery including pre-replication com-
plexes (pre-RC) for the viral replication initiation in the presence of 
LANA. The viral factor, LANA, is an essential factor, but its necessity 
has not been elucidated well. LANA binds with LANA-biding sites 
(LBS) and recruits origin recognition complexes (ORCs) on the 
viral replication origin (ori-P), which cannot account for necessity 
of the GC-rich element followed by LBS. Ohsaki and Ueda (2012) 
will give us a hint about this question.
Viral immune evasion system is very tactic to maintain its latency 
in case of herpesviruses. The maintenance of latency is then critical 
for the virus to wait for reactivation to produce daughter viruses, 
whose transition may a step for the viral oncogenic process. Lee 
et al. (2012) summarize KSHV immune evasion strategy and make 
a comment on the future landscape.
Kaposi’s sarcoma-associated virus mediated tumorigenesis 
including PEL and KS has been still unclear, though there are many 
reports on individual viral putative oncogenes. KSHV has not been 
reported to infect and immortalize and/or transform endothelial 
cells or peripheral blood mononuclear cells in vitro. And thus, we 
have not known how the viral genes with oncogenic potentials such 
as vFLIP, vCYC, vGPCR and so on in addition to LANA cooperate 
in the viral oncogenic process. DiMaio and Lagunoff (2012) address 
on this issue and look forward for this field.
It is 18 years since Kaposi’s sarcoma-associated virus (KSHV), also 
called human herpesvirus 8 (HHV-8), was found from Kaposis’ 
sarcoma (KS) by Chang et al. (1994). More than 8, 000 reports 
have been published so far and we have learned many things from 
this virus. I would like to say it is about time to look back previous 
studies and to think what to study next on the virus, and planed a 
topic to think what to study next on the virus for future.
Herpesviruses have relatively big genomes and encode a 100 
genes or so. Thus, the virion assembly/structure, gene expression 
regulation and attachment/entry are complicated and have known 
only an iceberg of them. Studying the details how the viruses run 
their life cycles and cause diseases in their processes will lead to 
exploring new therapeutic drugs/methods.
A viral life cycle starts from attachment on the susceptible cells 
and then, entry into the cells, followed by the viral gene expres-
sion, the genome replication, the particle assembly and finally the 
daughter viruses egress out of the cells. This process is skillfully 
built and all the viral genes are required for the process, though 
there are essential genes and non-essential ones. Viral pathogenesis 
could be established during this process by the interaction between 
viruses and host cells, and individual host systems such as immune 
system. In this topic, although I would like to cover all the processes, 
thankfully, 15 specialists in each field have contributed for this topic.
Polizzotto et al. (2012) described clinical manifestations of 
KSHV-associated diseases. So far, there were few reports on clini-
cal manifestations of primary KHSV infection. In this term, KSHV 
inflammatory cytokine syndrome (KICS) is a new concept and we 
might have been looked over an important disease sign on KHSV 
infection. We will have to be more careful about what happens in 
primary KSHV infection than before.
Fukumoto et al. (2011) describe KSHV infection from a patholo-
gist’s points of view. Pathologic study is very important to know 
what happens in the lesions. Currently, we are able to know what is 
going on only in the KSHV associated lesions such as Kaposi’s sar-
coma, multicentric Castleman’s disease and primary effusion lym-
phomas (PEL) of human samples suffered from KSHV infection, 
but once an infection model is established, chronological pathologic 
studies will provide a lot of information on how KSHV-associated 
diseases are formed.
Chakraborty et al. (2012) review the entry mechanism of KSHV 
into cells. In general, herpesviruses can infect various kinds of cells 
in vitro including non-human cell lines, but the infectivity to B 
lymphocyte originated cells is very inefficient. Their report will 
give us a hint why such phenomenon happens.
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MicroRNA is one of the hottest research fields even in KSHV. 
This kind of small RNA molecule seems to have profound effects on 
cellular processes and then viral activities but their details have not 
been elucidated totally. KSHV lytic and latent phases are regulated 
by viral but also cellular microRNAs. Two specialists; Liang et al. 
(2011) and Gottwein (2012) reveals the microRNA world of KSHV.
And finally, we have to think about treatment of KSHV-
associated tumors such as KS, PEL and a lympho-proliferative 
disease, multicentric Castleman’s disease. It should be very hard 
to treat these tumors in the immunodeficient setting. It will be 
desirable if KSHV specific strategy is designed, since these tumors 
are very tightly linked with KSHV infection. Dittmer et al. (2012) 
contribute for this theme and discuss about it.
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